

Report to:



Item: 8.4

Date of Meeting	27 th November 2020
Title of Report:	Controlled Drugs Annual Report 2019-20
Presented by:	Clare Linley, Interim Director of Nursing and Quality, Hull CCG
Author:	Kevin McCorry, Medicines Optimisation Pharmacist, NECS
STATUS OF TH	E REPORT:
То ар	prove To endorse
To rat	ify To discuss
То со	nsider For information
To no	te X
on the NHS En RECOMMENDA a That NHS Memoran b That the N the presc	this report is to update the NHS Hull Clinical Commissioning Group Board gland Single Operating Model for Controlled Drugs at a local level.
If yes, detail groun	
CCG STRATE	GIC OBJECTIVE
Objective 8 - Del	ivery of Statutory Duties.
	Pa

NHS Hull Clinical Commissioning Group Board

Short summary as to how the report links to the CCG's strategic objectives

This report is to update the NHS Hull Clinical Commissioning Group Board and provide assurances on the NHS England Single Operating Model for Controlled Drugs at a local level.

IMPLICATI	IMPLICATIONS:					
Finance	As per paper					
HR	None					
Quality	As per paper					
Safety	As per paper					

ENGAGEMENT:

NHS England Area Team and the Local Intelligence Network (LIN); GP Practices, Hull and East Riding Prescribing Committee, Humber Teaching NHS Foundation Trust, Hull University Teaching Hospitals NHS Trust, and City Health Care Partnership.

LEGAL ISSUES: (Summarise key legal issues / legislation relevant to the report)

NHS England Single Operating Model for Controlled Drugs 2013 Misuse of Drugs Act 1971 Misuse of Drugs Regulations 2001 (and subsequent amendment) Department of Health Guidance (2006) Human Medicines Regulations 2012 and amended 2013

EQUALITY AND DIVERSITY ISSUES: (summary of impact, if any, of CCG's duty to promote equality and diversity based on Equality Impact Analysis (EIA). **All** reports relating to new services, changes to existing services or CCG strategies / policies **must** have a valid EIA and will not be received by the Committee if this is not appended to the report)

	Tick relevant box
An Equality Impact Analysis/Assessment is not required for this report.	V
An Equality Impact Analysis/Assessment has been completed and approved by the lead Director for Equality and Diversity. As a result of performing the analysis/assessment there are no actions arising from the analysis/assessment.	
An Equality Impact Analysis/Assessment has been completed and there are actions arising from the analysis/assessment and these are included in section xx in the enclosed report.	

THE NHS CONSTITUTION: (How the report supports the NHS Constitution)

The report supports the delivery of the NHS Constitution as the commissioning of primary care services will aid in the delivery of the following principles, rights and NHS pledges:

- 1) The NHS aspires to the highest standards of excellence and professionalism
- 2) NHS works across organisational boundaries and in partnership with other organisations in the interests of patients
- 3) Quality of care
- 4) You have the right to expect NHS organisations to monitor, and make efforts to improve, the quality of healthcare they commission or provide.

1. INTRODUCTION

The purpose of this report is to update the NHS Hull Clinical Commissioning Group Board on the NHS England Single Operating Model for Controlled Drugs at a local level.

2. BACKGROUND

The Memorandum of Understanding outlines the responsibilities of NHS England/Area Team and the CCG. Each year the NHS Hull Clinical Commissioning Group Board receives an update to provide the CCG with a summary of the work undertaken in the previous year and assurance that each of the CCG's responsibilities has been delivered with the support of the North of England Commissioning Support (NECS) Medicines Optimisation Team through engagement with NHS England Area Team and the Local Intelligence Network (LIN).

3. INFORMATION

Responsibilities of NHS Hull CCG for the safe use of Controlled Drugs

NHS Hull CCG Responsibilities	Actions continuing during 2019-20
Name an individual as CD Lead to act as a focal point for liaison with the NHSE-YH lead CDAO in relation to the safe use and management of CDs.	Sarah Smyth, Director of Quality & Clinical Governance/Executive Nurse was the Lead for Controlled Drugs for Hull CCG until June 2020 and
	Deborah Lowe, Deputy Director of Quality and Clinical Governance / Lead Nurse
Ensure the CCG, its governing body and member practices are aware of who represents them on Local Intelligence Network (LIN) and how and when to raise concerns.	•
Play an active part in the LIN sharing intelligence as appropriate and taking action to improve the safe use of CDs.	Controlled alerts and learnings from the LIN have been circulated to all GP practices. Where a need for learning is identified the NECS Senior Medicines Optimisation Pharmacist or Medicines Optimisation Pharmacist or Locality Pharmacist and CCG CD Lead will agree a process for sharing the learning across the CCG based on the individual incident.
Follow guidance regarding recording and sharing intelligence with respect to well-founded concerns reported to any officer of the CCG including sharing with a responsible body.	All CD incidents reported via the Hull Datix system are reviewed by the NECS Medicines Optimisation team in conjunction with the CCG Quality Team. 1 CD incident was reported directly to the CCG via

NHS Hull CCG Responsibilities	Actions continuing during 2019-20
	the DATIX system.
Report Serious Incidents in line with guidance and Serious Incident policy.	No Serious Incidents have been reported
Take part in incident panels where appropriate as agreed with the NHSE-YH CDAO.	No incident panels to date but should this be necessary this would be communicated to the CCG by the NECS Senior Medicines Optimisation Pharmacist or Medicines Optimisation Pharmacist or Locality Pharmacist.
Participate in a system for learning from	Learning is circulated across the Yorkshire & Humber
CD incidents and sharing this learning.	region via the LIN.
Practice and prescriber level analysis of CD prescribing trends and investigation of outliers in line with assuring appropriate, safe and effective prescribing within the CCG. Report concerns to NHSE-YH CDAO as appropriate.	The NECS Medicines Optimisation Team monitors prescribing of CDs issued by GP practices/prescribers in the primary care setting via the PrescQIPP information.
Bring concerns about the safe use of CDs by other healthcare providers to the attention of the LIN or NHSE-NYH CDAO in line with intelligence sharing agreement.	Accountable Officers from local healthcare providers attend the six monthly LIN including HUTH, Humber and CHCP.
agreement.	All providers report incidents directly to the NHS England Y&H Area Team.
	The annual or biannual controlled drug reports from HUTH; CHCP; Humber are reviewed via CCG contracting/Quality meetings to provide assurances on controlled drug processes for the Hull CCG providers.
Alert NHSE-NYH CDAO of intelligence received regarding premises used in connection with the management or use of CDs which is not subject to inspection by other regulatory bodies.	No premises identified.
Support NHSE-NYH CDAO in ensuring adequate steps are taken to protect patients and the public if there are concerns about inappropriate or unsafe use of CDs by a person who is not providing services for any designated body, but who provides services in the LIN area.	None identified.

Controlled Drug Prescribing Data 2019/20

This is based on prescribing data sourced via PrescQIPP using data from NHS Business Services Authority (BSA). Data is presented collectively for April 2019 to March 2020.

Summary points on the prescribing data

- All controlled drug schedules Hull CCG has the 4th highest out of 6 CCGs re 2019/2020 cost per 1000 patients in the Ssustainability and Transformation Partnership (STP) (Figure 1).
- Schedule 2 Hull CCG has the 4rd highest out of 6 CCGs re: 2019/2020 cost per 1000
 patients in the STP (Figure 2). There has been a significant increase in items year on year
 in 2019/2020 this is due to the substance misuse services prescribing attribution changing
 to the CCG rather than the Local Authority in 2019/2020. The CCG do a recharge to the
 Local Authority as they are the responsible commissioner for substance misuse services.
- Schedule 2 injectables Hull CCG has the 5th highest out of 6 CCGs re: 2019/2020 cost per 1000 patients in the STP (Figure 3).
- Schedule 3 Hull has the 3rd highest out of 6 CCGs re: 2019/2020 cost per 1000 patients in the STP (Figure 4).
- Schedule 4 Hull CCG has the highest out of 6 CCGs re: 2019/2020 cost per 1000 patients in the STP (Figure 5).
- Schedule 5 Hull CCG has the 4th highest out of 6 CCGs re: 2019/2020 cost per 1000 patients in the STP (Figure 6).
- All controlled drug schedules GP practices Ranked in decreasing cost per 1000 patients: Note due to practice mergers during 2019/20 some practices are showing significant increases and decreases but this is due to these mergers (Figure 7).

Actions to address controlled drug items growth and cost growth

- Analgesia is a key therapeutic area which is included in the CCG Medicines Optimisation Work Plan in the 2020/2021 work plan. Historical prescribing behaviours and greater use of oxycodone, fentanyl patches and buprenorphine patches has led to the CCG being high cost per population controlled drug prescribing. Changing or titrating patients to other opioid options and dealing with the dependence issues created from continual opioid prescribing will not be easy and is likely to require significant extra resources to tackle.
- An opioid prescribing volume indicator was introduced as part of the 2019/2020 GP practice enhanced service - Extended Medicines Management Scheme; with the aim to reduce the volume of opioids prescribed in Hull CCG. This prescribing indicator will continue into 2020/2021.
- A hypnotics and anxiolytic prescribing volume indicator has been introduced as part of the 2020/2021 GP practice enhanced service - Extended Medicines Management Scheme with the aim to reduce the volume of hypnotics and anxiolytic prescribed in Hull CCG (schedule 3 controlled drugs)
- 4) The CCG introduced the implementation and delivery of the Campaign to Reduce Opioid Prescribing (CROP) project in 2019/2020 and this project will continue into 2020/2021 (this has been to a Council of Members meeting). The Campaign to Reduce Opioid Prescribing project was originally designed to assist general practices across West Yorkshire with opioid deprescribing in an effort to improve patient care and safety across the region. CROP involves education; audit and tools to support deprescribing and review for GP practices.
- 5) Network Contract Directed Enhanced Service Specification in 2020/21 Structured medication review (SMR) and Medicines Optimisation Service. This specification outlines how each Primary Care Network (PCN) will identify and prioritise patients who would

benefit from a SMR; one of the cohorts of patients to include for SMRs is 'Using potentially addictive pain management medication'.

All controlled drug schedules Figure 1

Select Commissioner Grouping:	Filte	er Commissioner(s):	Filter	Period(s):		Select CD Schedule:			
STP/ICS HUMBER, COAST AND VALE	All			(All)						
able showing monthly and overall YTD growth for All commissioners showing (All) controlled drugs										
					YT	D				
Commissioner	Total Items Last Year		Total Items This Year	Items per 1,000 patients this year	% Gowth in Items	Total Act Cost Last Year	Cost per 1,000 patients last year	Total Act Cost This Year		
NHS EAST RIDING OF YORKSHIRE CCG	476,733	1,554	476,746	1,554	0%	£3,806,463	£12,407	£3,829,863		
NHS HULL CCG	530,679	1,758	543,624	1,801	2%	£3,574,689	£11,843	£3,753,141		
NHS NORTH EAST LINCOLNSHIRE CCG	264,169	1,552	263,852	1,550	0%	£1,575,129	£9,253	£1,609,435		
NHS NORTH LINCOLNSHIRE CCG	307,334	1,698	299,820	1,657	-2%	£2,395,118	£13,236	£2,294,831		
NHS SCARBOROUGH AND RYEDALE CCG	219,184	1,811	217,285	1,795	-1%	£1,584,944	£13,095	£1,537,915		
NHS VALE OF YORK CCG	376,148	1,037	368,396	1,016	-2%	£3,416,883	£9,424	£3,285,450		

Schedule 2 Figure 2

Select Commissioner Grouping:):	Filter	Period(s):		Select CD Schedule:						
STP/ICS HUMBER, COAST AND VALE	All		All			Schedule	2				
Table showing monthly and overall YTD growth for All commissioners showing Schedule 2 controlled drugs											
					۲۲	D					
Commissioner	Total Items Last Year	ltems per 1,000 patients last year	Total Items This Year	Items per 1,000 patients this year	% Gowth in Items	Total Act Cost Last Year	Cost per 1,000 patients last year	Total Act Cost This Year			
NHS EAST RIDING OF YORKSHIRE CCG	75,825	247	74,829	244	-1%	£1,287,273	£4,196	£1,267,265			
NHS HULL CCG	90,007	298	112,214	372	25%	£1,193,558	£3,954	£1,304,021			
NHS NORTH EAST LINCOLNSHIRE CCG	32,703	192	33,568	197	3%	£514,009	£3,019	£506,116			
NHS NORTH LINCOLNSHIRE CCG	40,429	223	31,559	174	-22%	£890,589	£4,921	£809,961			
NHS SCARBOROUGH AND RYEDALE CCG	24,943	206	24,728	204	-1%	£481,353	£3,977	£447,839			
NHS VALE OF YORK CCG	39,992	110	39,903	110	0%	£992,844	£2,738	£940,875			

Schedule 2 Injectables Figure 3

Select Commissioner Grouping: STP/ICS HUMBER, COAST AND VALE	Filter Commissioner(s): All			Filter	Period(s):	Select CD Schedule: Schedule 2 injections					
able showing monthly and overall YTD growth for All commissioners showing Schedule 2 injections controlled drugs											
	YTD										
Commissioner	Total Items Last Year		Total Items This Year	Items per 1,000 patients this year	% Gowth in Items	Total Act Cost Last Year	Cost per 1,000 patients last year	Total Act Cost This Year			
NHS EAST RIDING OF YORKSHIRE CCG	2,117	7	2,278	7	8%	£59,281	£193	£61,22			
NHS HULL CCG	1,170	4	1,280	4	9%	£24,690	£82	£52,22			
NHS NORTH EAST LINCOLNSHIRE CCG	1,187	7	1,226	7	3%	£16,780	£99	£17,46			
NHS NORTH LINCOLNSHIRE CCG	831	5	937	5	13%	£19,824	£109	£22,15			
NHS SCARBOROUGH AND RYEDALE CCG	945	8	835	7	-12%	£15,878	£131	£9,28			
NHS VALE OF YORK CCG	1,517	4	1,726	5	14%	£25,156	£69	£24,11			

			Filter Period(s): All			Select CD Schedule: Schedule 3						
Fable showing monthly and overall YTD growth for All commissioners showing Schedule 3 controlled drugs												
				YT	D							
Total Items Last Year	ltems per 1,000 patients last year	Total Items This Year	Items per 1,000 patients this year	% Gowth in Items	Total Act Cost Last Year	Cost per 1,000 patients last year	Total Act Cost This Year					
143,213	467	145,175	473	1%	£1,035,726	£3,376	£985,325					
170,746	566	174,113	577	2%	£992,681	£3,289	£1,081,763					
78,542	461	77,540	455	-1%	£386,870	£2,273	£339,758					
96,301	532	97,524	539	1%	£591,967	£3,272	£482,564					
72,172	596	72,158	596	0%	£487,527	£4,028	£451,784					
141,903	391	140,219	387	-1%	£1,176,519	£3,245	£1,019,746					
	Total Items Last Year 143,213 170,746 78,542 96,301 72,172	Total Items Last Year Items per 1,000 patients last year 143,213 467 170,746 566 78,542 461 96,301 532 72,172 596	Total Items Last Year Items per 1,000 patients last year Total Items This Year 143,213 467 145,175 170,746 566 174,113 78,542 461 77,540 96,301 532 97,524 72,172 596 72,158	Total Items Last Year Items per 1,000 patients last year Total Items This Year Items per 1,000 patients this year 143,213 467 145,175 473 170,746 566 174,113 577 78,542 461 77,540 455 96,301 532 97,524 539 72,172 596 72,158 596	Total Items Last YearItems per 1,000 patients last yearTotal Items This YearItems per 1,000 % Gowth in Items143,213467145,17547311%170,746566174,1135772%78,54246177,540455-1%96,30153297,5245391%72,17259672,1585960%	Total Items Last Year Items per 1,000 patients last year Total Items This Year Items per 1,000 patients last year Total Act Cost Last Year 143,213 467 145,175 473 11% £1,035,726 170,746 566 174,113 577 2% £992,681 78,542 461 77,540 455 -1% £386,870 96,301 532 97,524 539 1% £591,967 72,172 596 72,158 596 0% £487,527	Total Items Last Year Items per 1,000 patients last year Total Items This Year Items per 1,000 patients last year Total Act Cost gatients last year Cost per 1,000 patients last year 143,213 467 145,175 473 11% £1,035,726 £3,376 170,746 566 174,113 577 2% £992,681 £3,289 78,542 461 77,540 455 -1% £386,870 £2,273 96,301 532 97,524 539 1% £591,967 £3,272 72,172 596 72,158 596 0% £487,527 £4,028					

<u>Schedule 4</u> Figure 5

Select Commissioner Grouping: STP/ICS HUMBER, COAST AND VALE				Filter Period(s): All			Select CD Schedule: Schedule 4			
Table showing monthly and overa	all YTD growth fo	or All commissi	oners showing	g Schedule 4 co	ntrolled drugs					
					YT	D				
Commissioner	Total Items Last Year	ltems per 1,000 patients last year	Total Items This Year	Items per 1,000 patients this year	% Gowth in Items	Total Act Cost Last Year	1 1	Total Act Cost This Year		
NHS EAST RIDING OF YORKSHIRE CCG	76,553	250	74,866	244	-2%	£638,251	£2,081	£578,109		
NHS HULL CCG	85,840	284	79,536	263	-7%	£641,750	£2,127	£526,674		
NHS NORTH EAST LINCOLNSHIRE CCG	43,472	255	42,619	250	-2%	£275,317	£1,617	£295,528		
NHS NORTH LINCOLNSHIRE CCG	47,343	262	47,248	261	0%	£364,369	£2,013	£367,074		
NHS SCARBOROUGH AND RYEDALE CCG	35,321	292	34,241	283	-3%	£236,938	£1,958	£216,659		
NHS VALE OF YORK CCG	57,232	158	54,956	152	-4%	£651,435	£1,797	£661,756		

Select Commissioner Grouping: STP/ICS HUMBER, COAST AND VALE	Filter Commissioner(s): All			Filter	Period(s):	Select CD Schedule: Schedule 5					
Table showing monthly and overall YTD growth for All commissioners showing Schedule 5 controlled drugs											
					Y	D					
Commissioner	Total Items Last Year	Items per 1,000 patients last year	Total Items This Year		% Gowth in Items	Total Act Cost Last Year		Total Act Cost This Year			
NHS EAST RIDING OF YORKSHIRE CCG	179,025	584	179,598	585	0%	£785,931	£2,562	£937,943			
NHS HULL CCG	182,916	606	176,481	585	-4%	£722,010	£2,392	£788,459			
NHS NORTH EAST LINCOLNSHIRE CCG	108,265	636	108,899	640	1%	£382,153	£2,245	£450,573			
NHS NORTH LINCOLNSHIRE CCG	122,430	676	122,552	677	0%	£528,368	£2,919	£613,077			
NHS SCARBOROUGH AND RYEDALE CCG	85,803	709	85,323	705	-1%	£363,249	£3,001	£412,350			
NHS VALE OF YORK CCG	135,504	374	131,592	363	-3%	£570,929	£1,575	£638,953			

All controlled drug schedules – GP practices – Ranked in decreasing cost per 1000 patients: Note due to practice mergers during 2019/20 some practices are showing significant increases and decreases but this is due to these mergers Figure 7

Practice	Total Items Last Year		Total Items This Year	ltems per 1,000 patients this year		Total Act Cost Last Year	Cost per 1,000 patients last year	Total Act Cost This Year	Cost per 1,000 patients this year	%Growth in Cost
B81040 DR JAD WEIR & PARTNERS	36,821	2,540	36,289	2,504	-1%		16,219	£224,937	15,519	-4%
B81112 JAMES ALEXANDER FAMILY PRACTICE	15,194	1,965	15,279	1,976	1%		14,587	£118,547	15,333	5%
B81054 CLIFTON HOUSE MEDICAL CENTRE	21,266	2,425	20,832	2,376	-2%	£135,308	15,433	£128,451	14,649	-5%
B81008 EAST HULL FAMILY PRACTICE	52,569	1,809	57,469	1,967	9%	£386,487	13,344	£404,649	13,847	5%
B81038 DR IA GALEA AND PARTNERS	14,630	1,957	14,756	1,973	1%	£107,696	14,407	£102,163	13,663	-5%
B81032 WILBERFORCE SURGERY	11,078	2,707	11,702	2,861	6%	£49,173	12,005	£52,700	12,881	7%
B81018 ORCHARD 2000 GROUP	23,483	2,619	22,035	2,458	-6%	£123,147	13,738	£112,406	12,537	-9%
B81011 KINGSTON HEALTH (HULL)	17,140	1,785	17,379	1,810	1%	£119,294	12,423	£119,179	12,407	0%
B81688 DR KV GOPAL'S PRACTICE	3,858	1,916	3,890	1,932	1%	£24,018	11,935	£24,800	12,317	3%
B81048 MODALITY PARTNERSHIP (HULL)	29,274	530	84,159	1,558	187%	£231,763	4,219	£637,846	11,786	175%
B81058 SYDENHAM GROUP PRACTICE	14,097	1,674	13,886	1,649	-1%	£95,639	11,357	£95,176	11,300	0%
B81020 THE SUTTON MANOR SURGERY	12,677	1,724	11,549	1,571	-9%	£89,232	12,135	£81,298	11,056	-9%
B81074 CITY HEALTH PRACTICE LTD	9,335	1,425	11,374	1,738	22%	£60,325	9,207	£71,524	10,933	19%
B81675 HAXBY GROUP CALVERT & NEWINGTON	16,694	1,523	17,399	1,588	4%	£118,358	10,807	£116,648	10,641	-1%
B81027 ST ANDREWS SURGERY	20,735	2,304	18,023	2,001	-13%	£118,268	13,107	£93,374	10,374	-21%
B81047 WOLSELEY MEDICAL CENTRE	9,423	1,305	10,501	1,453	11%	£68,873	9,538	£74,654	10,333	8%
B81002 CHP LTD - BRANSHOLME	5,164	1,567	4,314	1,315	-16%	£54,890	16,623	£33,450	10,208	-39%
B81119 GOOD HEART SURGERY	11,904	2,509	9,308	1,962	-22%	£70,482	14,853	£46,291	9,756	-34%
B81017 KINGSTON MEDICAL GROUP	24,306	1,552	28,474	1,822	17%	£122,192	7,801	£147,147	9,415	20%
B81046 THE BRIDGE GROUP PRACTICE	15,865	1,843	15,025	1,746	-5%	£83,677	9,722	£79,068	9,186	-6%
B81095 COOK BF	5,526	1,385	5,819	1,461	5%	£33,370	8,376	£36,513	9,150	9%
B81631 DRS RAUT AND THOUFEED	11,617	2,454	10,290	2,173	-11%	£45,017	9,510	£41,871	8,844	-7%
B81075 HASTINGS MEDICAL CENTRE	3,944	1,189	5,130	1,550	30%	£24,529	7,424	£27,796	8,379	13%
B81052 PRINCES MEDICAL CENTRE	6,946	1,041	7,364	1,104	6%	£64,373	9,661	£55,033	8,249	-15%
B81085 BURNBRAE MEDICAL PRACTICE	4,109	878	4,304	920	5%	£34,795	7,438	£37,151	7,941	7%
B81616 DR GT HENDOW'S PRACTICE	3,896	1,425	3,877	1,419	0%	£22,399	8,203	£21,258	7,777	-5%
B81635 LAURBEL SURGERY	3,293	973	3,565	1,054	8%	£26,713	7,913	£25,895	7,659	-3%
Y02747 HAXBY GROUP HULL	12,849	960	13,180	985	3%	£96,925	7,233	£98,649	7,376	2%
B81035 THE AVENUES MEDICAL CENTRE	10,047	1,495	9,946	1,480	-1%	£54,053	8,042	£49,151	7,318	-9%
B81097 DELTA HEALTHCARE	2,354	953	2,232	903	-5%	£16,294	6,536	£17,390	7,026	7%
B81645 EAST PARK PRACTICE	5,375	1,358	5,403	1,365	1%	£33,898	8,587	£23,718	5,988	-30%
B81066 DR GM CHOWDHURY'S PRACTICE	1,493	596	1,528	610	2%	£9,076	3,626	£8,345	3,335	-8%
B81080 DR GS MALCZEWSKI'S PRACTICE	683	337	461	227	-33%	£5,060	2,501	£4,520	2,220	-11%
B81104 NAYAR JK	1,016	138	1,384	188	36%	£8,019	1,087	£8,985	1,221	12%
B81056 THE SPRINGHEAD MEDICAL CENTRE	1,795	107	2	0	-100%	£19,043	1,137	£8	1	-100%
B81053 DIADEM MEDICAL PRACTICE	5,404	445	0	0	-100%	£37,213	3,067	£O	0	-100%

Note: due to practice mergers during 2019/20 some practices are showing significant increases and decreases but this is due to these mergers.

4. **RECOMMENDATIONS**

It is recommended:

- a) That NHS Hull CCG be assured that the responsibilities as outlined within the Memorandum of Understanding are being delivered.
- b) That the NHS Hull Clinical Commissioning Group Board notes the report relating to the prescribing of Controlled Drugs in NHS Hull CCG.

Glossary of Terms

- CD Controlled Drug (Named in Schedule 2 or 3 of the Misuse of Drugs Regulations 2001)
- CDAO Controlled Drugs Accountable Officer
- LIN Local Intelligence Network
- NECS North of England Commissioning Support